- Home
- IMPP vs XFOR Comparison
IMPP vs XFOR Comparison
Compare IMPP & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- XFOR
- Stock Information
- Founded
- IMPP 1981
- XFOR 2014
- Country
- IMPP Greece
- XFOR United States
- Employees
- IMPP N/A
- XFOR N/A
- Industry
- IMPP Marine Transportation
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMPP Consumer Discretionary
- XFOR Health Care
- Exchange
- IMPP Nasdaq
- XFOR Nasdaq
- Market Cap
- IMPP 99.2M
- XFOR 118.4M
- IPO Year
- IMPP N/A
- XFOR N/A
- Fundamental
- Price
- IMPP $2.62
- XFOR $0.19
- Analyst Decision
- IMPP
- XFOR Strong Buy
- Analyst Count
- IMPP 0
- XFOR 3
- Target Price
- IMPP N/A
- XFOR $2.83
- AVG Volume (30 Days)
- IMPP 157.6K
- XFOR 1.8M
- Earning Date
- IMPP 05-15-2025
- XFOR 05-01-2025
- Dividend Yield
- IMPP N/A
- XFOR N/A
- EPS Growth
- IMPP N/A
- XFOR N/A
- EPS
- IMPP 1.40
- XFOR N/A
- Revenue
- IMPP $147,479,980.00
- XFOR $2,557,000.00
- Revenue This Year
- IMPP $3.05
- XFOR $355.69
- Revenue Next Year
- IMPP $47.92
- XFOR $140.28
- P/E Ratio
- IMPP $1.87
- XFOR N/A
- Revenue Growth
- IMPP N/A
- XFOR N/A
- 52 Week Low
- IMPP $2.12
- XFOR $0.17
- 52 Week High
- IMPP $4.59
- XFOR $1.25
- Technical
- Relative Strength Index (RSI)
- IMPP 62.91
- XFOR 32.62
- Support Level
- IMPP $2.55
- XFOR $0.17
- Resistance Level
- IMPP $2.78
- XFOR $0.22
- Average True Range (ATR)
- IMPP 0.14
- XFOR 0.02
- MACD
- IMPP 0.04
- XFOR 0.01
- Stochastic Oscillator
- IMPP 75.87
- XFOR 32.26
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.